NON MUSCLE INVASIVE BLADDER CANCER

This study tests a new drug, TARA-002, given directly into the bladder for people with a high-grade type of bladder cancer that hasn't spread into the muscle. The goal is to see if it can make the cancer disappear and keep it away. About 131 adults who have not had enough success…

This study tests a new drug called cretostimogene in people with a type of bladder cancer that did not get better with standard therapy (BCG). The goal is to see if the drug can make tumors disappear and keep them from coming back. About 16 adults with high-risk, non-muscle invas…

This study tests two drugs, durvalumab and monalizumab, in people with a type of bladder cancer that hasn't spread into the muscle. The goal is to see if the combination can make the cancer disappear or stop it from growing. About 60 adults who have not responded to standard BCG …

This study compares a newer, single surgery using special dye and light (PDD-TURBT) against the standard approach of two surgeries for early-stage bladder cancer. About 112 adults with non-muscle invasive bladder cancer will be randomly assigned to either the new single-surgery m…

This early-stage study is testing a new drug, belzupacap sarotalocan, injected directly into bladder tumors to see if it's safe and doable for people with non-muscle-invasive bladder cancer. About 55 participants will receive the injection, sometimes with a laser, and be monitore…

This study tests a drug called Sac-TMT, given directly into the bladder, for people with a type of bladder cancer that hasn't spread into the muscle. The main goals are to check the drug's safety and find the best dose. About 32 people with recurrent low-grade tumors will take pa…

This study tests a new drug called 2141-V11 for safety in people with a type of bladder cancer that didn't get better with standard treatment. The drug is given directly into the bladder through a tube (catheter). About 55 people will take part to find the safest dose and see how…

This program provides access to an experimental treatment called cretostimogene for people with a type of bladder cancer that has not responded to standard BCG therapy. It is for patients with non-muscle invasive bladder cancer, specifically carcinoma in situ with or without high…

This early-stage study tests a new drug, PF-08052667, for adults with a type of bladder cancer that hasn't spread into the bladder muscle but is likely to return. The drug is given alone or with standard treatments like BCG and/or sasanlimab. The goal is to check safety and find …

This early-stage trial tests a new treatment for a type of bladder cancer that hasn't been helped by the usual therapy (BCG). The treatment uses tiny particles called micelles, which are coated with a targeting molecule (PLZ4) to deliver the chemotherapy drug paclitaxel directly …

This study compares several approved drugs for a type of bladder cancer that hasn't spread into the muscle. About 125 adults whose prior treatment stopped working will receive either a newer gene therapy or standard options. The goal is to see which drug best prevents the cancer …

This study tests whether adding bicalutamide (a drug used for prostate cancer) to standard BCG therapy can help prevent bladder tumors from coming back. It involves 160 men with early-stage bladder cancer who are already scheduled for BCG treatment. The goal is to see if the comb…

This early-stage trial tests a new drug called STM-416 that is applied directly into the bladder during surgery to remove cancerous growths. The study includes 75 adults with recurrent high-grade bladder cancer who are at high risk for the cancer coming back. The main goals are t…

This study tests whether a chemotherapy drug (Mitomycin C) placed directly into the bladder can replace surgery for people with a common, low-grade form of bladder cancer that keeps coming back. About 272 adults with recurrent Ta low-grade tumors will either get the chemo treatme…

This study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…

This study is for 200 adults with non-muscle invasive bladder cancer who are getting standard chemotherapy (MMC) or immunotherapy (BCG) directly into the bladder. Half will also receive a special bladder rinse called Hydeal Cyst® after each treatment. The goal is to see if this r…

This study tests whether people with a history of low-risk bladder cancer can safely replace some of their regular, invasive cystoscopy procedures with a simple urine test. The goal is to see if this approach reduces discomfort, anxiety, and the number of invasive procedures with…

This study is for people with non-muscle invasive bladder cancer who are getting BCG treatment directly into the bladder. Researchers want to see if the treatment causes mood changes by collecting blood and urine samples and having participants fill out mood questionnaires and da…

This study collects videos and data from 500 adults undergoing blue light cystoscopy for bladder cancer. The goal is to train an AI system to help doctors spot suspicious lesions more accurately during the procedure. No new treatments are tested; the focus is on gathering high-qu…

This study is creating a registry to see how doctors in France currently treat and follow patients with non-muscle-invasive bladder cancer. Researchers will track 8,000 adults to learn what works best and how to improve care. The goal is to find better ways to monitor the disease…

This study looks at how bacteria and the immune system interact in the bladder to understand different urinary conditions. Researchers will collect samples from 800 adults with and without bladder problems, including infections, pain, and cancer. The goal is to find patterns that…